Target intelligence / Profile preview

Capsid protein of Enterovirus D68

Molecular classification
Structural protein, Viral protein, Other
01

Overview

The **capsid protein of Enterovirus D68 (EV-D68)** comprises an icosahedral shell encapsulating the viral RNA genome, formed by 60 copies each of the structural proteins **VP1, VP2, VP3**, and **VP4**[6][7][10]. These proteins assemble into protomers (VP1-VP4), further forming the mature viral capsid (about 30 nm diameter)[1][4]. The outer surface is composed mainly of VP1–VP3, with a unique canyon structure surrounding the fivefold axes that serves as a primary site for host receptor binding (notably **sialic acid** and **ICAM-5**)[1][2]. VP4 is internal, associated with the capsid interior and genome. The capsid undergoes conformational changes upon receptor binding or acidification, facilitating viral uncoating and genome release[1][7]. This protein complex is considered a therapeutic target for antivirals such as pleconaril (which binds to and stabilizes the capsid, blocking uncoating) and for neutralizing antibodies that block receptor engagement or induce premature uncoating[10][1]. The capsid is also a key antigenic target for vaccine development and host immune responses against EV-D68; changes in capsid structure or sequence may influence viral pathogenesis, immune escape, and resistance to therapy.

Other names
EV-D68 capsid proteinEnterovirus D68 capsidStructural proteins VP1–VP4 of EV-D68
02

Mechanism of action

Inhibition of viral attachment to host receptors by blocking the canyon or other capsid sites[1][3] Stabilization of the capsid to prevent conformational transitions required for uncoating[10] Premature triggering of uncoating transitions leading to noninfectious particles

03

Biological functions

Viral cell entryViral genome encapsidationUncoating for viral genome releaseHost immune recognition
04

Disease associations

Infection
05

Safety considerations

Viral resistance mutations in capsid proteinOff-target effects of broad capsid-binding compoundsLack of current approved therapeutics; clinical safety yet to be established[10]
06

Interacting drugs

Pleconaril[10]

2 more in the full profile.

07

Biomarkers

Viral RNA (for detection of infection; not specific to capsid)No established patient stratification biomarker for capsid inhibition

Beyond the preview

Go deeper on Capsid protein of Enterovirus D68.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Capsid protein of Enterovirus D68.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call